- WuXi XDC Cayman Inc. has entered a strategic collaboration with Earendil Labs, granting an exclusive global licence to its WuXiTecan-2 payload-linker technology platform in a deal valued at up to approximately $885 million.
- WuXi XDC will support CMC development and manufacturing under its integrated CRDMO platform, while Earendil Labs will lead clinical development, regulatory submissions and commercialisation.
WuXi XDC Cayman Inc. has announced a strategic collaboration with Earendil Labs focused on its proprietary WuXiTecan-2 payload-linker technology platform for antibody-drug conjugates (ADCs). The agreement grants Earendil Labs an exclusive global licence to the technology for use against multiple specific targets, with a total potential deal value of up to approximately $885 million, including upfront, development, regulatory, and sales milestone payments. WuXi XDC will also be eligible to receive tiered royalties on net sales following commercialisation.
Under the agreement, Earendil Labs will use the WuXiTecan-2 platform to conjugate antibodies and bispecific antibodies discovered through its AI-driven discovery platform. The collaboration aims to accelerate the development of next-generation ADC candidates targeting autoimmune diseases, cancer and other conditions with unmet medical needs.
WuXi XDC will leverage its integrated CRDMO and contract manufacturing capabilities to support Chemical, Manufacturing and Controls (CMC) development and manufacturing of ADC components within the collaboration. Earendil Labs will focus on product development, global regulatory submissions and commercialisation activities. The partnership combines WuXi XDC’s ADC technology platform with Earendil Labs’ AI-based antibody discovery and development expertise.
“This collaboration not only fully demonstrates the value of our WuXiTecan-2 payload-linker technology platform but also marks another significant milestone for WuXi XDC in empowering cutting-edge innovation alongside our partners.” He added that the partnership is intended to accelerate research, development and commercialisation of next-generation ADCs for patients worldwide.
Jimmy Li, PhD, CEO of WuXi XDC
